Melanoma screening: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Blanked the page)
No edit summary
 
(10 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
{{Melanoma}}
{{CMG}} {{AE}} [[User:Sara Mohsin|Sara Mohsin, M.D.]]
==Overview==
The 1992-1994 free [[American Academy of Dermatology|American Academy of Dermatology's]] National [[Skin]] [[Cancer (disease)|Cancer]] Early [[Detection theory|Detection]] and [[Screening (medicine)|Screening]] Program provided broad [[skin]] [[Cancer (disease)|cancer]] [[Education|educational]] [[Information science|information]] to general [[Public health|public]] and enabled thousands of free [[Expert Patient Programme|expert]] [[skin]] [[Cancer (disease)|cancer]] [[Examination|examinations]]. The 2001-2005 [[American Academy of Dermatology]] National [[Melanoma]]/[[Skin]] [[Cancer (disease)|Cancer]] [[Screening (medicine)|Screening]] Program emphasized on the use of HARMM [[criteria]] to identify the higher-[[RiskMetrics|risk]] [[Subgroup analysis|subgroup]] of [[skin]] [[Cancer (disease)|cancer]] [[Screening (medicine)|screening]] [[Population (statistics)|population]] via [[Assessment and Plan|assessment]] of multiple [[risk factors]] for [[MM]] hence, both [[Reduced|reducing]] the [[Cost-effectiveness|cost]] & increasing the [[Yield (chemistry)|yields]] for suspected [[MM]] in [[Future interests (actuarial science)|future]] [[mass]] [[Screening (medicine)|screening]] [[Initiation (chemistry)|initiatives]]. [[Melanoma]] [[Genetics]] Program identifies the [[genetic]] [[causes]] of [[skin]] [[Cancer (disease)|cancer]], and provides [[genetic counseling]] to the [[Individual growth|individuals]] with [[strong]] [[family history]] of [[melanoma]]. [[Dermoscopy]] [[Usage analysis|usage]] [[Improving agent|improves]] the [[Ability grouping|ability]] of [[Primary care physician|primary care physicians]] to [[triage]] [[lesions]] [[Suggestion|suggestive]] of [[skin]] [[Cancer (disease)|cancer,]] thus saving from [[Unnecessary Fuss|unnecessary]] [[Expert Patient Programme|expert]] [[Consultation|consultations]]. [[Combination therapy|Combination]] of [[dermoscopy]] and short-term [[Sequential analysis|sequential]] [[Digital dictation|digital]] [[dermoscopy]] [[imaging]] (SDDI) in a [[Primary care provider|primary care setting]] doubles the [[Sensitivity (tests)|sensitivity]] for [[melanoma]] [[diagnosis]] and [[Lead|leads]] to >50% [[chance]] of [[reduction]] in [[excision]] or [[Reference|referral]] of [[benign]] [[pigmented lesions]].


==Screening==
According to different [[Study design|studies]] going on for so many [[Year|years]], following [[data]] is available regarding the different [[Method of Levels|methods]]/tools and their [[Effective method|effectiveness]] for [[skin]] [[Cancer (disease)|cancer]] [[Screening (medicine)|screening]]:
* From 1992 to 1994, free [[American Academy of Dermatology|American Academy of Dermatology's]] National [[Skin]] [[Cancer (disease)|Cancer]] Early [[Detection theory|Detection]] and [[Screening (medicine)|Screening]] Program was launched which provided broad [[skin]] [[Cancer (disease)|cancer]] [[Education|educational]] [[Information science|information]] to general [[Public health|public]] and enabled almost 750,000 free [[Expert Patient Programme|expert]] [[skin]] [[Cancer (disease)|cancer]] [[Examination|examinations]] which mostly found out thin, [[Localized disease|localized]] stage 1 [[melanomas]] with high [[Project Halo|projected]] [[Five year survival rate|5-year survival rate]]<ref name="urlSkin Cancer (Melanoma) Treatment Program - Massachusetts General Hospital, Boston, MA">{{cite web |url=https://www.massgeneral.org/cancer/services/treatmentprograms.aspx?id=1196&utm_source=google&utm_medium=cpc&utm_campaign=cancerppc&utm_content=Skin_Cancer_Tests&utm_term=%2Bskin%20%2Bcancer%20%2Bscreening&gclid=Cj0KCQjwyLDpBRCxARIsAEENsrLfUiAniaSP1Yn6UijTzqDMp0KFhlTv2Eikg5a9TyVSGnWkmoiA3bsaAqNfEALw_wcB |title=Skin Cancer (Melanoma) Treatment Program - Massachusetts General Hospital, Boston, MA |format= |work= |accessdate=}}</ref><ref name="pmid8647990">{{cite journal| author=Koh HK, Norton LA, Geller AC, Sun T, Rigel DS, Miller DR et al.| title=Evaluation of the American Academy of Dermatology's National Skin Cancer Early Detection and Screening Program. | journal=J Am Acad Dermatol | year= 1996 | volume= 34 | issue= 6 | pages= 971-8 | pmid=8647990 | doi=10.1016/s0190-9622(96)90274-1 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8647990  }} </ref>
* From 2001 to 2005, [[American Academy of Dermatology]] National [[Melanoma]]/[[Skin]] [[Cancer (disease)|Cancer]] [[Screening (medicine)|Screening]] Program was launched which led to the conclusion that HARMM [[criteria]] can be [[Usage analysis|used]] to identify the higher-[[RiskMetrics|risk]] [[Subgroup analysis|subgroup]] of [[skin]] [[Cancer (disease)|cancer]] [[Screening (medicine)|screening]] [[Population (statistics)|population]] via [[Assessment and Plan|assessment]] of multiple [[risk factors]] for [[MM]] , which will not only [[Reduced|reduce]] the [[Cost-effectiveness|cost]] but will also increase the [[Yield (chemistry)|yields]] for suspected [[MM]] in [[Future interests (actuarial science)|future]] [[mass]] [[Screening (medicine)|screening]] [[Initiation (chemistry)|initiatives]]<ref name="pmid17490783">{{cite journal| author=Goldberg MS, Doucette JT, Lim HW, Spencer J, Carucci JA, Rigel DS| title=Risk factors for presumptive melanoma in skin cancer screening: American Academy of Dermatology National Melanoma/Skin Cancer Screening Program experience 2001-2005. | journal=J Am Acad Dermatol | year= 2007 | volume= 57 | issue= 1 | pages= 60-6 | pmid=17490783 | doi=10.1016/j.jaad.2007.02.010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17490783  }} </ref>
* [[Melanoma]] [[Genetics]] Program identifies the [[genetic]] [[causes]] of [[skin]] [[Cancer (disease)|cancer]], and also provides [[genetic counseling]] to the [[Individual growth|individuals]] having a [[strong]] [[family history]] of [[melanoma]]<ref name="pmid19739523">{{cite journal| author=Gauwerky K, Ruzicka T, Berking C| title=[Skin cancer screening at the family doctor's office]. | journal=MMW Fortschr Med | year= 2009 | volume= 151 | issue= 25 | pages= 38-42; quiz 43 | pmid=19739523 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19739523  }} </ref><ref name="pmid24908774">{{cite journal| author=Treiber N, Huber MA, Scharffetter-Kochanek K, Schneider LA| title=[Early detection of skin cancer]. | journal=MMW Fortschr Med | year= 2014 | volume= 156 | issue= 4 | pages= 37-40 | pmid=24908774 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24908774  }} </ref><ref name="pmid15884241">{{cite journal| author=Mierzwa T, Zegarski W, Placek W, Zegarska B| title=[Skin cancer screening program in the population of Bydgoszcz]. | journal=Wiad Lek | year= 2004 | volume= 57 Suppl 1 | issue=  | pages= 211-4 | pmid=15884241 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15884241  }} </ref><ref name="urlSkin Cancer (Melanoma) Treatment Program - Massachusetts General Hospital, Boston, MA" /><ref name="pmid31106016">{{cite journal| author=Bajaj S, Wolner ZJ, Dusza SW, Braun RP, Marghoob AA, DeFazio J| title=Total Body Skin Examination Practices: A Survey Study Amongst Dermatologists at High-Risk Skin Cancer Clinics. | journal=Dermatol Pract Concept | year= 2019 | volume= 9 | issue= 2 | pages= 132-138 | pmid=31106016 | doi=10.5826/dpc.0902a09 | pmc=6502292 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31106016  }} </ref><ref name="pmid21757257">{{cite journal| author=Argenziano G, Zalaudek I, Hofmann-Wellenhof R, Bakos RM, Bergman W, Blum A et al.| title=Total body skin examination for skin cancer screening in patients with focused symptoms. | journal=J Am Acad Dermatol | year= 2012 | volume= 66 | issue= 2 | pages= 212-9 | pmid=21757257 | doi=10.1016/j.jaad.2010.12.039 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21757257  }} </ref><ref name="urlSkin Cancer Screening: MedlinePlus Lab Test Information">{{cite web |url=https://medlineplus.gov/lab-tests/skin-cancer-screening/ |title=Skin Cancer Screening: MedlinePlus Lab Test Information |format= |work= |accessdate=}}</ref>
* [[Dermoscopy]] [[Usage analysis|usage]] [[Improving agent|improves]] the [[Ability grouping|ability]] of [[Primary care physician|primary care physicians]] to [[triage]] [[lesions]] which are [[Suggestion|suggestive]] of [[skin]] [[Cancer (disease)|cancer]] and saves from [[Unnecessary Fuss|unnecessary]] [[Expert Patient Programme|expert]] [[Consultation|consultations]]<ref name="pmid16622262">{{cite journal| author=Argenziano G, Puig S, Zalaudek I, Sera F, Corona R, Alsina M et al.| title=Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer. | journal=J Clin Oncol | year= 2006 | volume= 24 | issue= 12 | pages= 1877-82 | pmid=16622262 | doi=10.1200/JCO.2005.05.0864 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16622262  }} </ref>
* [[Combination therapy|Combination]] of [[dermoscopy]] and short-term [[Sequential analysis|sequential]] [[Digital dictation|digital]] [[dermoscopy]] [[imaging]] (SDDI) in a [[Primary care provider|primary care setting]] doubles the [[Sensitivity (tests)|sensitivity]] for [[melanoma]] [[diagnosis]] and also [[Lead|leads]] to >50% [[chance]] of [[reduction]] in [[excision]] or [[Reference|referral]] of [[benign]] [[pigmented lesions]]<ref name="pmid19747359">{{cite journal| author=Menzies SW, Emery J, Staples M, Davies S, McAvoy B, Fletcher J et al.| title=Impact of dermoscopy and short-term sequential digital dermoscopy imaging for the management of pigmented lesions in primary care: a sequential intervention trial. | journal=Br J Dermatol | year= 2009 | volume= 161 | issue= 6 | pages= 1270-7 | pmid=19747359 | doi=10.1111/j.1365-2133.2009.09374.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19747359  }} </ref><ref name="pmid19832836">{{cite journal| author=van der Rhee JI, Bergman W, Kukutsch NA| title=The impact of dermoscopy on the management of pigmented lesions in everyday clinical practice of general dermatologists: a prospective study. | journal=Br J Dermatol | year= 2010 | volume= 162 | issue= 3 | pages= 563-7 | pmid=19832836 | doi=10.1111/j.1365-2133.2009.09551.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19832836  }} </ref><ref name="pmid30521682">{{cite journal| author=Dinnes J, Deeks JJ, Chuchu N, Ferrante di Ruffano L, Matin RN, Thomson DR et al.| title=Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults. | journal=Cochrane Database Syst Rev | year= 2018 | volume= 12 | issue=  | pages= CD011902 | pmid=30521682 | doi=10.1002/14651858.CD011902.pub2 | pmc=6517096 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30521682  }} </ref><ref name="pmid30521691">{{cite journal| author=Ferrante di Ruffano L, Takwoingi Y, Dinnes J, Chuchu N, Bayliss SE, Davenport C et al.| title=Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults. | journal=Cochrane Database Syst Rev | year= 2018 | volume= 12 | issue=  | pages= CD013186 | pmid=30521691 | doi=10.1002/14651858.CD013186 | pmc=6517147 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30521691  }} </ref><ref name="pmid30521690">{{cite journal| author=Ferrante di Ruffano L, Dinnes J, Deeks JJ, Chuchu N, Bayliss SE, Davenport C et al.| title=Optical coherence tomography for diagnosing skin cancer in adults. | journal=Cochrane Database Syst Rev | year= 2018 | volume= 12 | issue=  | pages= CD013189 | pmid=30521690 | doi=10.1002/14651858.CD013189 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30521690  }} </ref>
==References==
{{Reflist|2}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Dermatology]]
[[Category:Surgery]]

Latest revision as of 17:50, 8 July 2020

Melanoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Melanoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Melanoma screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Melanoma screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Melanoma screening

CDC on Melanoma screening

Melanoma screening in the news

Blogs on Melanoma screening

Directions to Hospitals Treating Melanoma

Risk calculators and risk factors for Melanoma screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sara Mohsin, M.D.

Overview

The 1992-1994 free American Academy of Dermatology's National Skin Cancer Early Detection and Screening Program provided broad skin cancer educational information to general public and enabled thousands of free expert skin cancer examinations. The 2001-2005 American Academy of Dermatology National Melanoma/Skin Cancer Screening Program emphasized on the use of HARMM criteria to identify the higher-risk subgroup of skin cancer screening population via assessment of multiple risk factors for MM hence, both reducing the cost & increasing the yields for suspected MM in future mass screening initiatives. Melanoma Genetics Program identifies the genetic causes of skin cancer, and provides genetic counseling to the individuals with strong family history of melanoma. Dermoscopy usage improves the ability of primary care physicians to triage lesions suggestive of skin cancer, thus saving from unnecessary expert consultations. Combination of dermoscopy and short-term sequential digital dermoscopy imaging (SDDI) in a primary care setting doubles the sensitivity for melanoma diagnosis and leads to >50% chance of reduction in excision or referral of benign pigmented lesions.

Screening

According to different studies going on for so many years, following data is available regarding the different methods/tools and their effectiveness for skin cancer screening:

References

  1. ↑ 1.0 1.1 "Skin Cancer (Melanoma) Treatment Program - Massachusetts General Hospital, Boston, MA".
  2. ↑ Koh HK, Norton LA, Geller AC, Sun T, Rigel DS, Miller DR; et al. (1996). "Evaluation of the American Academy of Dermatology's National Skin Cancer Early Detection and Screening Program". J Am Acad Dermatol. 34 (6): 971–8. doi:10.1016/s0190-9622(96)90274-1. PMID 8647990.
  3. ↑ Goldberg MS, Doucette JT, Lim HW, Spencer J, Carucci JA, Rigel DS (2007). "Risk factors for presumptive melanoma in skin cancer screening: American Academy of Dermatology National Melanoma/Skin Cancer Screening Program experience 2001-2005". J Am Acad Dermatol. 57 (1): 60–6. doi:10.1016/j.jaad.2007.02.010. PMID 17490783.
  4. ↑ Gauwerky K, Ruzicka T, Berking C (2009). "[Skin cancer screening at the family doctor's office]". MMW Fortschr Med. 151 (25): 38–42, quiz 43. PMID 19739523.
  5. ↑ Treiber N, Huber MA, Scharffetter-Kochanek K, Schneider LA (2014). "[Early detection of skin cancer]". MMW Fortschr Med. 156 (4): 37–40. PMID 24908774.
  6. ↑ Mierzwa T, Zegarski W, Placek W, Zegarska B (2004). "[Skin cancer screening program in the population of Bydgoszcz]". Wiad Lek. 57 Suppl 1: 211–4. PMID 15884241.
  7. ↑ Bajaj S, Wolner ZJ, Dusza SW, Braun RP, Marghoob AA, DeFazio J (2019). "Total Body Skin Examination Practices: A Survey Study Amongst Dermatologists at High-Risk Skin Cancer Clinics". Dermatol Pract Concept. 9 (2): 132–138. doi:10.5826/dpc.0902a09. PMC 6502292 Check |pmc= value (help). PMID 31106016.
  8. ↑ Argenziano G, Zalaudek I, Hofmann-Wellenhof R, Bakos RM, Bergman W, Blum A; et al. (2012). "Total body skin examination for skin cancer screening in patients with focused symptoms". J Am Acad Dermatol. 66 (2): 212–9. doi:10.1016/j.jaad.2010.12.039. PMID 21757257.
  9. ↑ "Skin Cancer Screening: MedlinePlus Lab Test Information".
  10. ↑ Argenziano G, Puig S, Zalaudek I, Sera F, Corona R, Alsina M; et al. (2006). "Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer". J Clin Oncol. 24 (12): 1877–82. doi:10.1200/JCO.2005.05.0864. PMID 16622262.
  11. ↑ Menzies SW, Emery J, Staples M, Davies S, McAvoy B, Fletcher J; et al. (2009). "Impact of dermoscopy and short-term sequential digital dermoscopy imaging for the management of pigmented lesions in primary care: a sequential intervention trial". Br J Dermatol. 161 (6): 1270–7. doi:10.1111/j.1365-2133.2009.09374.x. PMID 19747359.
  12. ↑ van der Rhee JI, Bergman W, Kukutsch NA (2010). "The impact of dermoscopy on the management of pigmented lesions in everyday clinical practice of general dermatologists: a prospective study". Br J Dermatol. 162 (3): 563–7. doi:10.1111/j.1365-2133.2009.09551.x. PMID 19832836.
  13. ↑ Dinnes J, Deeks JJ, Chuchu N, Ferrante di Ruffano L, Matin RN, Thomson DR; et al. (2018). "Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults". Cochrane Database Syst Rev. 12: CD011902. doi:10.1002/14651858.CD011902.pub2. PMC 6517096 Check |pmc= value (help). PMID 30521682.
  14. ↑ Ferrante di Ruffano L, Takwoingi Y, Dinnes J, Chuchu N, Bayliss SE, Davenport C; et al. (2018). "Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults". Cochrane Database Syst Rev. 12: CD013186. doi:10.1002/14651858.CD013186. PMC 6517147 Check |pmc= value (help). PMID 30521691.
  15. ↑ Ferrante di Ruffano L, Dinnes J, Deeks JJ, Chuchu N, Bayliss SE, Davenport C; et al. (2018). "Optical coherence tomography for diagnosing skin cancer in adults". Cochrane Database Syst Rev. 12: CD013189. doi:10.1002/14651858.CD013189. PMID 30521690.

Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Melanoma_screening&oldid=1622940"